NCT00779545已完成2 期
Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 455
- 主要终点
- Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2
研究概览
简要总结
This is a multicenter, randomized, double-blind within the dose level, parallel group comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to examine the minimal effective dose, the recommended dose, and the dosing regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of mongoloid race residing in Japan who satisfy all of the following criteria:
- •Patients having symptoms of allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining the informed consent during the pretreatment observation period.
- •Patients in whom the skin or specific IgE test is positive and the cytological examination for eosinophils in nasal discharge or nasal challenge test is positive.
- •Out-patients aged 16 years or over at the time of obtaining the informed consent.
- •Male or female.
- •Patients from whom the informed consent can be obtained in writing (or the informed consent can be obtained from the patient's legally acceptable representative, if under 20 years).
- •Patients who can daily complete the nasal allergy diary.
排除标准
- •Patients who meet any of the following exclusion criteria are not included in the present study:
- •Patients with a complication of tuberculous disease or lower respiratory tract infection, or patients with a complication of acute upper respiratory tract inflammation or acute laryngopharyngitis which the (sub) investigator considers necessary to treat at the time of enrollment in the treatment.
- •Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available.
- •Patients with unhealed nasal septum ulcer, nasal surgery, or nasal trauma.
- •Patients with hypersensitivity to steroids and mometasone furoate.
- •Patients who are pregnant, nursing, or possibly pregnant, or who desire to become pregnant during the study period.
- •Patients with severe hepatic, renal, or cardiac disorder, blood disease, diabetes, hypertension, or other serious complication, suffering from problems with systemic condition.
- •Patients in whom pollen is an overlapping allergen and the study is planned to be implemented in the pollen release season.
- •Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis.
- •Patients with a complication of nose disease which may interfere with efficacy evaluation of the investigational product.
- •Patients who were complicated by acute upper respiratory tract inflammation during the 7-day observation period prior to enrollment which may affect the nasal symptoms.
- •Patients who have previously received mometasone furoate nasal spray.
- •Patients who have participated in clinical trial of other investigational product(s) within 4 months before obtaining the informed consent or are participating at present.
- •Patients in whom prior medication effective against allergic rhinitis was withdrawn not long enough before initiation of treatment with the investigational product or the preceding medication cannot be withdrawn.
- •Patients who are being treated with specific desensitization therapy or nonspecific allassotherapy or in whom such the therapy was withdrawn within 3 months before obtaining the informed consent (except for patients receiving the maintenance therapy at present in whom the therapy began more than 6 months before obtaining the informed consent).
- •Other patients whom the (sub) investigator judged to be inappropriate for participation in the present study.
研究组 & 干预措施
Mometasone furoate nasal spray 100 mcg QD
Experimental
干预措施: Mometasone furoate (Drug)
Mometasone furoate nasal spray 200 mcg QD
Experimental
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
干预措施: Placebo (Drug)
Mometasone furoate nasal spray 100 mcg QD
Experimental
干预措施: Placebo (Drug)
Mometasone furoate nasal spray 200 mcg QD
Experimental
干预措施: Mometasone furoate (Drug)
Mometasone furoate nasal spray 400 mcg QD
Experimental
干预措施: Placebo (Drug)
Mometasone furoate nasal spray 400 mcg QD
Experimental
干预措施: Mometasone furoate (Drug)
Mometasone furoate nasal spray 100 mcg BID
Experimental
干预措施: Mometasone furoate (Drug)
Mometasone furoate nasal spray 200 mcg BID
Experimental
干预措施: Mometasone furoate (Drug)
结局指标
主要结局
Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2
时间窗: After 2 weeks of treatment
次要结局
- Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching)(After 1 and 2 weeks of treatment)
- QOL score(At initial day of treatment and after 2 weeks of treatment)
- Laboratory tests(From initial day of treatment until treatment is stopped.)
- Adverse events(From initial day of treatment until 7-10 days after treatment is stopped.)
- Overall improvement(After 1 and 2 weeks of treatment)
研究者
相似试验
已完成
2 期
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent AsthmaAsthmaNCT01555151Novartis Pharmaceuticals739
已完成
1 期
A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female VolunteersTreatment of the Signs and Symptoms of Seasonal Allergic RhinitisNCT02109185Mylan Pharmaceuticals Inc1,307
已完成
3 期
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and NauseaVomitingNauseaNCT00272285Astellas Pharma Inc287
已完成
1 期
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior UveitisNon-Infectious Anterior UveitisNCT02309385Aciont Inc44
已完成
2 期
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT00403286Dey457